Login:
Share:
Email Facebook Twitter

Add Summit Corp to quick picks

Summit Corp Share Price (SUMM)



Share Price Information for Summit Corp (SUMM)


Share Price: 9.00Bid: 8.75Ask: 9.25Change: 0.00 (0.00%)No Movement on Summit Corp
Spread: 0.50Spread as %: 5.71%Open: 9.00High: 9.00Low: 9.00Yesterday’s Close: 9.00
InfoCFDs vs Share Trading - Download your Free Guide from LSE Markets
When trading CFDs, Forex, and Spread bets, it is possible to lose more than your initial deposit.


Summit Corporation Plc Ord 1P

Summit Corp is listed in the FTSE AIM All-Share
Summit Corp is part of the Pharmaceuticals & Biotechnology sector




Intraday Summit Corp Share Chart


Intraday Summit Corp Share Price Chart


Share Price SpacerPrice
9.00

Share Price SpacerBid
8.75

Share Price SpacerAsk
9.25

Share Price SpacerChange
0%0.00

Share Price SpacerVolume
385,817

Share Price SpacerOpen
9.00

Share Price SpacerHigh
9.00

Share Price SpacerLow
9.00

Share Price SpacerClose
9.00

Share Price SpacerCurrency
GBX

3 Month Summit Corp Share Graph


3 Month Summit Corp Share Price Graph


Currency Issue Country Shares in Issue Market Capitalisation Market Size
GBX GB 821.23m £73.91m 50,000

52 Week High 20.00 52 Week High Date 26-SEP-2013
52 Week Low 3.88 52 Week Low Date 29-MAY-2013

# Trades Vol. Sold Vol. Bought PE Ratio Earnings Dividend Yield
21 280,603 105,214 -6.716 -1.34 0.00 0.00


London South East Users info for Summit Corp



Users who hold SUMM also hold: Tower Resources, Red Rock, Sareum, Victoria Oil


Date
Time
Trade Prc
Volume
Buy/Sell
Bid
Ask
Value
 

23-Apr-14
16:20:49
9.25
5,000
Buy* 
8.75
9.25
462.50
Trade Type:
Ordinary

23-Apr-14
16:18:33
9.0725
39,373
Buy* 
8.75
9.25
3,572
Trade Type:
Ordinary

23-Apr-14
14:58:26
9.0725
19,061
Buy* 
8.75
9.25
1,729
Trade Type:
Ordinary
Bargain conditions apply


*Buys and Sells are calculated on the difference between the trade price and the current mid price. As such, they can occasionally be incorrect.

View more Summit Corp trades >>

Directors Deals for Summit Corp (SUMM)
Trade DateActionNotifierPriceCurrencyAmountHolding
23-Jul-13Placing
Trade Notifier Information for Summit Corporation
Frank Armstrong held the position of Non-Executive Director at Summit Corporation at the time of this trade.
 Frank Armstrong
5GBX50,00050000
23-Jul-13Placing
Trade Notifier Information for Summit Corporation
Jim Mellon held the position of Non-Executive Director at Summit Corporation at the time of this trade.
 Jim Mellon
5GBX20,000,00045000001
03-Jul-13Placing
Trade Notifier Information for Summit Corporation
Barry Price held the position of Non-Executive Chairman at Summit Corporation at the time of this trade.
 Barry Price
5GBX500,0001514615
View more Summit Corp directors dealings >>

Date/Time
Author
Subject
Share Price
Opinion
Wed 16:51
rotivatorman
RE: RNS
9.00
No Opinion

My guess is they will keep us waiting until Friday…..perhaps even Friday afternoon
Wed 16:36
Albino
RE: RNS
9.00
Hold

I certainly hope so.
Wed 16:22
Top_mav
RNS
9.00
No Opinion

Are we going to get a RNS this week ! Getting impatient
Tue 15:04
Moneymunch
fast track
9.13
Strong Buy

Early access to medicines and treatments could help Cheltenham man with Duchenne Muscular Dystrophy “I do miss walking, of course, and dream I still can sometimes.”Those are the words of Daniel Baker, 38, from the Reddings, who suffers from Duchenne Muscular Dystrophy (DMD), a disease which causes muscle degeneration. If complications occur with the respiratory system, it can sometimes prove fatal.But Daniel is hoping a cure can be found in this lifetime, even if there might only be “a small chance”.The Government agreed earlier this year that new medicines and treatments which could treat serious illnesses will be fast-tracked to patients, after years of campaigning by a Gloucestershire man, Les Halpin.Les, from Tetbury, was a motor neurone disease sufferer who has fought for years for early access. He died last September at the age of 56.The new scheme will allow those with seriously debilitating conditions the lifeline of trying new medicines years before they go through the normal licensing process.One of those companies who will be looking to apply is Summit, a pharmaceutical company developing treatments for DMD.The company’s lead drug has finished phase one studies in healthy volunteers and it is now being tested on DMD boys in four hospitals in UK. The next study will start later this year, something Daniel said he would volunteer for.He said: “I hope this is the start of something new for medicine, not just DMD, but any life-threatening illness. I understand the need for trials, but really when you’re facing something life limiting, it’s worth the risks, as long as the patient agrees and is made fully aware that something could go drastically wrong.Read more:  http://www.gloucestershireecho.co.uk/Early-access-medicines-treatments-help-Cheltenham/story-20989916-detail/story.html#ixzz2zch8gfNJ
Tue 09:41
TheNinja
Me too
9.00
No Opinion

What can we expect later this year?
Tue 08:09
optomisticme
Morning all...
9.00
Buy

Newbie for this type of share, jumped in this morning after hearing about SUMM from moneymunch on another BB. Trying to cram in as much information as I can about the company and all reads well enough so far for me to invest. Still loads to understand. GLA OPTO

Share prices shown are taken at time of message posting.
NEWThread ViewThread View
View more share chat for Summit Corp (SUMM) >>
Please Login or Register to post messages

Share Trading BrochureRequest your Free brochures on share dealing, spread betting and CFDs




Sign up for Live Prices


CD02WL.001.081313


Datafeed and UK data supplied by NBTrader and Digital Look. While London South East do their best to maintain the high quality of the information displayed on this site,
we cannot be held responsible for any loss due to incorrect information found here. All information is provided free of charge, 'as-is', and you use it at your own risk.
The contents of all 'Chat' messages should not be construed as advice and represent the opinions of the authors, not those of London South East Limited, or its affiliates.
London South East does not authorise or approve this content, and reserves the right to remove items at its discretion.